Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2015 | Pages:
1147 | Publisher: RESEARCH IMPACT TECHNOLOGIES
Industry: Biotechnology | Report Format: Electronic (PDF)
This report covers both products and services in the RNAi industry. The global RNAi market is analyzed by Tools/Products and Applications for each of the geographic regions- North America, Europe, Asia-Pacific and Rest of World. The RNAi Tools/Products are further segmented into Design/Software (miRNA Target Scan, miRNA Analysis Software, and Design Software), Synthesis (Expression Vectors, Chemical, miRNA Isolation, Dicer/RNAseIII, and In Vitro), Delivery (Vector Based, Transfection Reagents, and Electroporation), Monitoring/Optimizing (Primers for RTqPCR, Controls, and miRNA Detection Tools), and Libraries (Human, Mouse, and Rat). Application by Research (Functional Genomics, Metabolism, and Protein Chemistry), Therapeutics (Oncology, Neurology, Ophthalmology, and Virology) and Drug Development (Target Identification, Target Validation, and Drug Mechanism) are also analyzed. Business profiles of major companies are discussed in the report. The report serves as a guide to global RNAi industry covering 280 plus companies that are engaged in RNAi synthesis, R&D, therapeutics, test kits, tools and services. Major Research Organizations and Universities serving the industry are also covered in the Corporate Directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, mergers and acquisitions, ethical issues, regulatory affairs, and other areas of concern is also covered in the report. Estimations and predictions are provided by geographic regions with exclusive graphical representations illustrated for 485 plus exhibits.
Table of Contents I. SCOPE AND METHODOLOGY 1 II. REPORT SYNOPSIS 3 Introduction to RNAi 3 RNAi - Nature’s Way of Silencing Gene 3 Definition 4 Summary 4 RNAi – The Main Objectives of Our Study 5 RNAi – Some Basics 5 History of RNAi 7 RNAi – Origins and Discovery 8 Segmentation of RNAi 10 Exhibit 1. Segmentation of Global RNAi Market by Application and Tools/Products 10 Exhibit 2. Segmentation by Application 10 Exhibit 3. Segmentation by Tools/Products 10 Facts About RNAi 11 Relation between siRNA Length and siRNA Function 18 Functional Significance of siRNA Length 18 Is siRNA Length Influential of siRNA Function? 19 Use of RNAi in Mammalian Systems 19 RNAi - Global Market Analysis 22 Exhibit 4. RNAi– Global Market Estimations & Predictions (2005 -2020) in US$ Million 22 Exhibit 5. List of Major RNAi Global Companies 23 III. MARKET DYNAMICS 24 Global RNAi Market Overview 24 RNAi - A Breakthrough in Molecular Biology 24 Nobel Prize 24 RNAi – Gene Silencing Mechanism 24 esiRNA Technology 26 RNAi – The Corporate Scenario 26 RNAi – The Commercial Potential 28 RNAi – The Pharma Perspective 31 RNAi – Unlike Stem Cell Therapy 31 Global RNAi Market 32 Exhibit 6. RNAi – Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 32 Exhibit 7. RNAi – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 33 North America RNAi Market 34 Exhibit 8. RNAi – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 34 Exhibit 9. RNAi – North American Market Shares (2010, 2015 & 2020) for United States and Canada 35 United States RNAi Market 35 Canadian RNAi Market 35 Exhibit 10. List of Major RNAi Companies in North America 35 European RNAi Market 37 Exhibit 11. RNAi – European Market Estimations & Predictions (2005 - 2020) by Geographic Region for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 37 Exhibit 12. RNAi – EuropeanMarket Shares (2010, 2015 & 2020) by Geographic Region for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 38 German RNAi Market 39 United Kingdom RNAi Market 39 Belgian RNAi Market 39 French RNAi Market 39 Russian RNAi Market 39 Exhibit 13. List of Major European RNAi Companies 39 Asia-Pacific RNAi Market 40 Exhibit 14. RNAi –Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 40 Exhibit 15. RNAi – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 41 Australian RNAi Market 41 Japanese RNAi Market 41 China RNAi Market 41 Indian RNAi Market 41 South Korean RNAi Market 41 Exhibit 16. List of Major Asia-Pacific RNAi Companies 42 Rest of World RNAi Market 43 Exhibit 17. RNAi – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries in US$ Million 43 Exhibit 18. RNAi – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries in US$ Million 44 Brazilian RNAi Market 44 Israeli RNAi Market 44 South African RNAi Market 44 Exhibit 19. List of Major Rest of World RNAi Companies 44 RNAi - Market Trends 45 RNAi – An Emerging Class of Drugs in Pharmaceuticals 45 Biotech/Pharma Industry’s Interest in RNAi 45 RNAi’s Functionality 45 Sourcing and Market Potential 45 Marketing Strategy 45 Economic Possibilities 45 Mission Ahead for RNAi 46 Biotech Companies Realize to Gain Billions of Dollars by Applying RNAi Technology 47 RNAi: Focus on Modeling Cellular Systems 49 Initial Stages of Mammalian RNAi Screening 50 Development of Signaling Pathways Using a Mammalian RNAi Screen 53 Identification of Components in a Biological Process: RNA interference 53 Component Discovery 53 Reporter Assays and High-Content Image-based Screening 54 Component Validation and Classification 55 An Outlook on Binary Genetic Interactions with RNAi 58 Hypothetical RNAi Screening for Cell-Growth Regulators 59 Prospects of Knockdown Technology 60 RNA interference (RNAi) 61 Introduction 61 Redefinition of RNA 61 Knockdown of Genes 62 RNAi on a Large Scale 63 RNAi: Beyond Machinery 63 Silencing Diseases 64 Principle Behind RNAi 65 Delivery 66 Area of Concern 67 Major Companies in RNAi Industry 68 Allele Biotechnology and Pharmaceuticals, Inc. (USA) 68 Alnylam Pharmaceuticals, Inc. (USA) 68 Arrowhead Research Corporation (USA) 71 Asuragen, Inc. (USA) 72 Benitec Ltd. (Australia) 74 Bioneer Corporation (South Korea) 75 Cenix Bioscience GmbH (Germany) 76 Cepheid (USA) 78 Clontech Laboratories, Inc. (USA) 78 CytoPathfinder, Inc. (Japan) 79 GlaxoSmithKline PLC (UK) 80 InvivoGen (USA) 81 Life Technologies Corporation (USA) 81 Marina Biotech, Inc. (USA) 84 Mirus Bio LLC (USA) 85 Novus Biologicals, LLC (USA) 85 Promega Corporation (USA) 86 Qiagen N.V (The Netherlands) 87 Quark Pharmaceuticals, Inc. (USA) 87 Regulus Therapeutics, Inc. (USA) 89 Rosetta Genomics Laboratories (Israel) 90 RXi Pharmaceuticals Corporation (USA) 91 Silence Therapeutics plc (UK) 92 SomaGenics, Inc. (USA) 93 Sylentis SA (France) 94 Tekmira Pharmaceuticals Corporation (Canada) 95 Major Activities in RNAi Market 96 Cenix BioScience Enters into Research Service Agreement with Bayer Pharma AG 96 Rosetta Genomics and Marina Biotech Enters into Strategic Collaboration 96 Alnylam Completes Acquisition of Sirna Therapeutics 96 Rosetta Genomics Enters into Collaboration with Rabin Medical Center of Clalit Health Services for microRNA-Based Assay for Chronic Allograft Dysfunction Following Kidney Transplantation 97 Regulus Renews Strategic Alliance with Sanofi 97 InteRNA Technologies, UCB and University of Bonn Enters into Collaboration to Study the Role of microRNAs in Neurodegenerative Diseases 98 Tekmira Enters into Development Agreement on Delivery Technology for Agricultural Applications 98 Alnylam Establishes Transformational Alliance with Genzyme to Develop and Commercialize RNAi Therapeutics as Genetic Medicines 98 Marina Biotech and Mirna Therapeutics Revises microRNA-based Therapeutics License Agreement 99 Rosetta Genomics Enters into Master Service Provider Agreement with a Major International Biopharmaceutical Company 99 Rosetta Genomics Includes Romania and Turkey to Expand microRNA Cancer Testing Services Distribution Agreement with GeneKor 100 Rosetta Genomics Enters into Sponsored Research Agreement with Ramot at Tel Aviv University 100 Collaboration between MultiCell Technologies and Genisphere for Targeted Delivery of MCT- 485, a Noncoding miRNA to Treat Cancer 100 Servier Expands Strategic Alliance with miRagen Therapeutics 101 Cenix BioScience Enters into Collaboration with Debiopharm for Identification of Predictive Biomarkers 101 Santaris Pharma Enters into Discovery Collaboration with Bristol-Myers Squibb for RNA-targeted Medicines 101 miRagen Therapeutics Obtains Exclusive License to Intellectual Property from the University of Glasgow 101 Benitec Biopharma Out-Licenses RNAi Technology to Regen 102 Arcturus Therapeutic Takes Over Marina’s UNA Patent Estate 102 Thermo Fisher Scientific Plans to Acquire Life Technologies Corporation 102 Medicines Company Enters into a RNAi Therapeutics Partnership with Alnylam 103 Santaris Pharma A/S and miRagen Therapeutics Expands Global Strategic Partnership 104 Benitec Acquires Tacere Therapeutics 104 Syngenta Acquires Devgen 104 Silence Therapeutics Signs Contract with MiReven Pty Ltd. 105 Regulus Therapeutics Enters into Collaboration with AstraZeneca 105 Alnylam Receives Payment from GlaxoSmithKline in the VaxiRNA Partnership 105 Alnylam and Ascletis Enters into Partnership to Develop ALN-VSP 106 Genisphere and LIMR Extends Partnership on miRNA Biomarker Development 106 Alnylam and Ascletis Enters into Partnership to Develop ALN-VSP 106 Quark Pharmaceuticals and Silence Therapeutics Extends Contract with Pfizer to Develop Silence’s AtuRNAi in a Novel Indication 107 Alnylam and PBL Signs License Agreement for Baulcombe and Hamilton RNAi Patent 107 Calimmune Out-Licenses ddRNAi Technology to Benitec Biopharma Signs 108 Bachem and BioSpring Team Up to Develop Oligonucleotide Peptide Conjugates for R&D 108 Arrowhead Research Corporation and Axolabs GmbH Signs Strategic Alliance and Master Services Agreement for RNAi Therapeutics 108 Cenix BioScience Expands Operations in the United States 108 OPKO Health Acquires CURNA Inc. 109 Alnylam and Arrowhead Enters into Collaboration and Licensing Agreement 109 Marina Biotech Signs License Agreement with Mirna Therapeutics for Development of microRNA-based Therapeutics 109 Genisphere Out-Licenses RNA Amplification and MicroRNA Labeling Technologies to Affymetrix 110 Benitec Plans to Develop Gene Therapy for Oculopharyngeal Muscular Dystrophy 110 Cenix Signs Agreement with SYGNIS for Developing RNAi Research 110 Affymetrix and Genisphere Sign Strategic Licensing Agreement for Proprietary MicroRNA Reagents 110 Alnylam and GSK Collaborates on RNAi Technology for Vaccine Production 111 Arrowhead Research Acquires Roche RNA Assets and Research Site 111 Rosetta Genomics Collaborates with Avatao Biotech for the Marketing of miRview Tests in China 112 Servier and Miragen Collaborates in a US$ 352 Million Deal for MicroRNA-targeting Drugs 112 Silence Therapeutics Signs Agreement with Mirna Therapeutics for the Evaluation of Delivery of New microRNA Therapeutics 112 Tekmira Secures Global Exclusive License to Novel RNAi Platform 113 Tekmira in association with Bristol-Myers Squibb Expands Collaboration to include Broader Applications of LNP Technology 113 Cenix BioScience Enters into Collaboration and Technology License Agreement for In Vivo siRNA Delivery 113 Precision NanoSystems and Alnylam Forms New Delivery Collaboration 114 AlCana Technologies, The University of British Columbia, and Alnylam Extend Delivery Research Collaboration 114 Marina Biotech Plans to Co-Develops and Co-Commercializes RNAi based Therapies for Bladder Cancer treatment with Debiopharm 114 AVI BioPharma Alliances with Karolinska Institutet to Detect RNA-based Therapeutic Candidates for XDR-TB treatment 115 Silence Therapeutics and miRagen Therapeutics Signs Agreement for the Evaluation of Delivery of Novel microRNA-based Therapeutics 115 Alnylam, Medtronic, & CHDI Foundation in Collaboration to Advance RNAi Therapy to Treat Huntington's Disease 115 Quark Signs Licensing Option Agreement with Novartis for p53 Suppressor Drug QPI-1002 116 Nitto Denko Inks Collaboration Agreement with Quark to Develop a new siRNA Anti-fibrotic Drug 116 Santaris Pharma and miRagen Therapeutics Collaborate for Developing microRNA-targeted Medicines 116 Sanofi-Aventis and Regulus in Major Strategic Alliance on microRNA Therapies 117 Royal Philips Signs Research Agreement with RXi to Undertake Joint Research on Novel Image-Guided Therapy Concepts based on RNAi 117 siRNA Delivery Collaboration between Silence Therapeutics and AstraZeneca Extended 118 MDRNA Buys Cequent Pharmaceuticals 118 Silence Therapeutics Expands siRNA Delivery Collaboration Dainippon Sumitomo 118 Collaboration between GSK and Isis Pharmaceuticals for RNA Therapeutics to Counteract Rare and Infectious Diseases 118 MDRNA Gains BNA Patents for Widening the RNAi-Drug Discovery Platform 119 Regulus Therapeutics and GSK Establishes New Collaboration for Development and Commercialization of microRNA Therapeutics Targeting miR-122 119 MDRNA Extends Collaboration with VPC for Expanding the Bladder Cancer Program 119 Alnylam and Roche Advance RNAi Therapeutic Collaboration Phase of Landmark 2007 Alliance 120 Alnylam and KOKEN Enters into Licensing Agreement for Kreutzer-Limmer Patents 120 AXA Diagnostics Procures Italian Marketing Rights to Rosetta Genomics’ Diagnostics Tests 120 Santaris Pharma A/S Collaborates with Shire plc for Developing RNA-based Medicines 120 Alnylam Extends RNAi Therapeutics Collaboration with Novartis 121 Eurogentec Establishes New Facility for Oligo Synthesis 121 Isis and Alnylam in New Collaboration for Development of Single-Stranded RNAi Technology 121 MDRNA Inks a Licensing Agreement with Novartis for RNAi Delivery Technology 122 Cenix BioScience Collaborates with Boehringer Ingelheim for developing RNAi based Target Discovery Technology 122 Alnylam and Cubist Forms Strategic Collaboration to Develop and Commercialize RNAi Therapeutics Targeting RSV Infection 122 Alnylam Forms Collaboration with UCSF to Investigate Therapeutic Silencing of Key Gene Implicated in Uveal Melanoma 123 Affymetrix Acquires Panomics 123 Thermo Collaborates with Genentech for Development of siRNA Therapeutics 123 Alnylam Enters into Collaboration with Max Planck Institute 124 Roche Buys Mirus to Reinforce Study on RNAi Delivery 124 Thermo Fisher Scientific Buys Open Biosystems, Creating Unmatched RNAi Platform 124 Alnylam and Kyowa Hakko Collaborates to Develop and Commercialize ALN-RSV01 in Asia 125 Alnylam and Takeda Enters into Alliance for RNAi Therapeutics 125 Rosetta Inks Agreement with West Coast CLIA Certified Lab for Developing and Validating Tests 125 Asuragen Establishes New Company, Mirna Therapeutics 125 GlaxoSmithKline Enters Into Partnership Agreement with Regulus To Develop microRNA Targeted Therapeutics for Inflammatory Diseases treatment 126 Silence Therapeutics Enters into Agreement with AstraZeneca for the Development of Novel Approaches for siRNA Drug Delivery 126 Nastech Pharmaceutical Allocates its RNA-based Intellectual Property to its Subsidiary 127 RXi Pharmaceuticals Acquires Exclusive Rights to RNAi Sequences to Genes 127 Columbia University Medical Center and Rosetta Genomics in Development Collaboration 127 Asuragen Offers Newly Developed microRNA Services 127 Invitrogen Corp. and RXi Pharmaceuticals in Collaboration Agreement for Enhancement of RNAi Technology… 128 Exiqon’s Locked Nucleic Acids Licensed to Applied Biosystems 128 New Series of siRNA Developed by Applied Biosystems 128 Thermo Fisher Scientific and Lentigen Collaboration for Technology Development 128 Universite de Montreal to Study RNAi through Collaboration with Sigma-Aldrich 129 Isis and Alnylam Join Hands to Establish Regulus Therapeutics 129 RNAi Center Funding in Massachusetts 129 Silence Therapeutics Enters into Partnership with AstraZeneca 129 RXi Pharma Signs License Agreement with Cold Spring Harbor Laboratory 130 Two-Year Agreement between Mirus Bio and Pfizer for Evaluation of RNAi Delivery Technology 130 RXi Pharma Receives RNAi Assets from Parent Company 130 Applied Biosystems Launches the StepOne™ Real-Time PCR System 130 Nastech Acquires Exclusive Rights to RNAi Intellectual Property and Technology 131 Artemis Enters into Deal with Merck for Production of RNAi Mouse Models 131 Senetek Enters into Agreement with Poland’s IBCPAS for Treating Brain Tumors 131 Merck Buys Entire Stake in Sirna Therapeutics 132 Joint Effort to make a New Facility for Proteomics Profiling and Drug Effects in Human Cells 132 Framework Agreement signed Between Cenix BioScience and Merck KGaA 133 Invitrogen Launches Advanced Transfection Reagents 133 Calando Picks Agilent for siRNA production 133 Alnylam Receives Biodefense Contract worth US$ 23 million from Government Agency… 134 Bio-Rad Enters into Alliance with Integrated DNA Technologies for Developing RNAi… 134 Dharmacon Associates with Amaxa for Improved Delivery of siRNA into Complex Cell Types… 134 QIAGEN Enters into Alliance with CytoPathfinder for developing novel equipments for high-throughput RNAi screening… 134 Sirna Signs an Agreement with GSK for Developing RNAi based Drugs for Respiratory Disease Treatment…. 135 Applied Biosystems Acquires Complete Stake in the Ambion’s Research Products Division… 135 Nastech Acquires Galenea along with Galenea’s IP and Technology Rights … 135 Ambion Enters into Alliance with GE Healthcare for Reinforcing the study on Micro-RNA Microarray… 136 Non-Exclusive License Agreement Signed Between Alnylam Pharma and Eurogentec 136 Ambion Furnishes Cepheid with Licenses of Armored RNA… 136 Ambion Extends Partnership with Wyeth for the Development and Supply of RNA… 137 Major Product Innovations/Launches in RNAi Market 138 Exiqon Introduces LNA™ microRNA Mimics with No Off-target Effect 138 AstraZeneca Selects a New Pre-Clinically Validated microRNA Oncology Target 138 FDA Grants Additional Orphan Drug Status to ALN-AT3, an RNAi Therapeutic Product of Alnylam to Treat Hemophilia 138 Israeli Office of the Chief Scientist Funds Rosetta Genomics and Ramot Tel Aviv University’s Development of microRNA Oncology Therapy 139 Alnylam Attains Additional Orphan Drug Status for ALN-AT3, an RNAi Therapeutic from U.S. FDA for the Treatment of Hemophilia 139 Arrowhead Initiates Phase I Trial of RNAi Therapeutic - ARC-520 for Chronic Hepatitis B Infection Treatment 139 Alnylam Releases Positive Superior Outcome for ALN-TTRsc for Treating TTR-Mediated Amyloidosis 140 Dicerna Added Patent Claims Widening Coverage of Extended Dicer Substrate Therapeutic Structures 140 Alnylam Releases Novel Pre-clinical Data on ALN-AT3, for the Treatment of Hemophilia and Rare Bleeding Disorders 140 Alnylam Presents Positive Phase II Data for ALN-TTR02, for TTR-Mediated Amyloidosis (ATTR) Treatment 141 Alnylam Scientists Reports Pre-Clinical Findings with ALN 141 EGEN Reports Positive Results from the Rat Model of Pulmonary Arterial Hypertension (PAH) Study 141 Arrowhead Gains Patent Allowance for DPC siRNA Delivery System including Peptide Backbone 141 Dicerna Receives First Patent in Japan Related to Dicer Substrate siRNA Molecules 142 Arrowhead RNAi Candidate ARC-520 exhibits over 90% decrease in Circulating HBV DNA in Chimpanzee with Chronic Hepatitis B 142 Dicerna Attains Patent Issuance for DsiRNAs Directed at a Key Cancer Regulator, the KRAs Gene 142 Kyowa Hakko Kirin Selects Second DsiRNA Therapeutic Candidate for Development 143 SomaGenics Receives Patent for sshRNA Technology and Two New Small Business Innovation NIH Grants 143 Alnylam Attains Notice of Allowance from USPTO for New Patents from the Tuschl II Patent Estate including RNAi Therapeutics 143 Patent Allowance of Dicerna Claims Covering of Extended Dicer Substrate Therapeutic Structures 144 Carnegie and UMASS Receives Broad U.S. Patent for RNA Interference 144 InteRNA Technologies Granted Notice of Allowance for miRNA Sequences 144 US Patent Concerning RNAi Granted to Carnegie Institution and UMASS Medical School 145 Alnylam Receives Orphan Drug Designation from USFDA for ALN-TTR02 145 Sirnaomics Receives NIH SBIR Funds to Develop siRNA Therapeutics 145 Biosearch Technologies Releases Advanced RNA FISH Design Software 146 Phalanx Biotech Launches miRBase r18 based microRNA OneArray® Microarray 146 Firefly BioWorks Develops miRNA Detection Technology Using Funds from Private and Public Organizations 146 Alnylam Commences Phase I Clinical Study of ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) to Treat TTR-Mediated Amyloidosis (ATTR) 146 Tekmira Expands Product Pipeline With RNAi Therapy to Treat Alcohol Dependence 147 Altogen Biosystems Launches Pancreas-targeted siRNA In Vivo Transfection Kit 147 Tekmira Receives Key Patents Broadly Covering LNP Formulations and Mitigation of Immune Stimulation 148 Tekmira Initiates TKM-Ebola Phase I Clinical Trial 148 Benitec Biopharma and Medistem Technologies Announces Successful Stem Cell based Treatment for RA 148 Asuragen Launches miRInform® Pancreas Test for Detecting Cancer 149 Arrowhead Issued Patent covering siRNA Inhibitors of HIF-2a (EPAS1) 149 Innovative Method to Monitor RNAi Activity in Blood Samples Discovered at Alnylam 149 Alnylam Files Clinical Trial Application for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin to Treat Transthyretin-Mediated Amyloidosis 149 Dicerna Pharmaceuticals Announces Selection of First DsiRNA Therapeutic Candidate 149 USPTO Issues Patents for Lentiviral Vector and SMaRT RNA Platforms to VIRxSYS 150 Alnylam Pharmaceuticals Issues InterfeRx™ Intellectual Property License to Sylentis to Develop and Commercialize RNAi Therapeutics 150 Alnylam Expands "Alnylam 5x15" RNAi Therapeutic Pipeline with ALN-APC, an RNAi Therapeutic Targeting Protein C to Treat Hemophilia 151 Regulus Therapeutics Identifies Third microRNA Target to Trigger a Preclinical Milestone Payment from GSK 151 Life Technologies Generates Novel Drug Delivery Technology for Therapeutic Applications 151 LC Sciences Introduces V17 MicroRNA Microarrays 151 Benitec Limited Receives RNA Interference Patent in Japan 152 Tekmira Announces USPTO Issuance of Key Patents Covering LNP Manufacturing Process and Mitigation of siRNA immune stimulation 152 Bioo Scientific Introduces the new NEXTflex Small RNA Sequencing Kit for NGS Library Prep 152 Asuragen Introduces miRNA Biofluids Service 153 Affymetrix Introduces Next-Generation microRNA Solution GeneChip® miRNA 2.0 Array 153 New US Patent Issued to Silence Therapeutics Covering Fundamental RNA Interference Technology Presently in Several Clinical Trials 153 Cenix BioScience Receives Grant for R&D 154 Regulus Therapeutics Accredited with Federal Grant Awards for microRNA Therapeutics Designed for Fibrosis and Hepatitis C Viral Infection Treatment 154 RXi Pharmaceuticals Receives US$ 1 Million in IRS Grants to Improve RNAi Therapeutics 155 Life Technologies Introduces Advanced DNA and RNA Quantitation System 155 Tekmira Receives Key Patents covering LNP Manufacturing and Mitigation of siRNA Immune stimulation 155 Regulus Therapeutics Attains Supplementary Patents on microRNA Therapeutics for the Treatment of Hepatitis C Virus (HCV) Infection 156 Successful Grant of Further Hepatitis C RNAi Patent in the United States 156 Silence Therapeutics Receives New Patents Covering siRNA Sequences for RNA Interference Therapeutics 156 Promega Enhances Sensitivity for RNA Quantification with New GoTaq® 2-Step RT-qPCR 157 Marina Biotech Receives the US Patent for Amphoteric Liposomal siRNA Delivery Technology 157 Ocimum Biosolutions Provides Innovative Microrna Microarray Technology Solutions 158 Expansion of RNAi Structural Modification IP Portfolio Achieved Through Receipt of New U.S. Patent by Silence Therapeutics 158 RXi Pharmaceuticals Receives NIH Grant for Advancing RNAi Therapeutics 158 Affymetrix Launches QuantiGene® ViewRNA for In Situ Multiplex Gene Expression Analysis 159 Silence Therapeutics Announced the Issuance of New US Patent Broadly Covering Methods for Enhancing Silencing Activity of RNAi Therapeutics 159 Alnylam Secures Intellectual Property and Technology for RNAi Applications in Vaccine Research and Development 160 Benitec Limited Receives Hepatitis C RNA Interference Patent in the United States 160 Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States 161 Regulus Therapeutics Gains sole License for Intellectual Property to microRNA-21 for Heart, Liver, and Kidney Diseases 161 Kylin Therapeutics Granted pRNAi Technology Patent 161 Alnylam Granted Additional Tuschl II Patent in Japan 161 Regulus Therapeutics Obtains Exclusive License for Intellectual Property on Immuno-inflammatory microRNAs from the California Institute of Technology 162 Rosetta Genomics Receives Additional Patent 162 Bioo Scientific Unveils the patent pending T3™ Conjugation Kit for Targeted siRNA Delivery In Vivo 162 Thermo Fisher Scientific Initiates New Grant Scheme for RNAi Discovery 163 OPKO Health Issued US Patent Covering Use and Administration of Anti-HIF 1 Alpha siRNAs 163 Sigma-Aldrich Launches MISSION® esiRNA 163 Affymetrix in Association with Genisphere Launches Best-in-Class Solution for microRNA Expression Research 163 GeneCopoeia Launches GenomeWide MicroRNA (miRNA) Functional Analysis Tools 164 Promega Launches pmirGLO Dual-Luciferase miRNA Target Expression Vector for microRNA Study 164 Alnylam Acquires Nucleonics Patent Assets 165 USPTO Grants Core RNAi Patent to Silence Therapeutics 165 Calando Receives US Patent for CALAA-01 166 Alnylam Grants New InterfeRx™ Intellectual Property License to Calando 166 Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Related to microRNA Antagonists for Treatment of Inflammatory Diseases 166 Open Biosystems Unveils Decode RNAi Viral Screening Pools 166 Calando Attains Chinese Patent Rights for Methods and Compositions for Therapeutic Use of RNA Interference 167 Thermo Fisher Scientific Launches a New RNA-Interference Technology 167 Alnylam Grants Shanghai GenePharma License to Kreutzer-Limmer Patents 167 Alnylam Granted New Patent Covering RNAi Therapeutics in the UK 168 Qiagen Launches RNA Purification Kit 168 RXi Pharmaceuticals Granted Australian Patent Application License 168 RXi Pharmaceuticals Signs License Agreement with TriLink Biotechnologies for RNA Chemistry Technologies 168 Sigma-Aldrich Introduces LentiExpress™ Technology for High-Throughput RNAi Screening 169 Rosetta Genomics is Issued a Second Patent for MicroRNAs 169 Rosetta Genomics Signs Collaboration Agreement with Ben Gurion University 169 US Government Signs $38.6 Million Contract with Alnylam 169 Open Biosystems Launches New shRNAmir Library for RNA Interference 170 Quark Pharmaceuticals Presents Positive Results in Pre-Clinical Studies of Systemic RNAi Compound in ARF 170 Alnylam and Medtronic Advance Collaboration on Drug-Device Combinations to Treat Neurodegenerative Diseases 171 Oligo PRO™ 24HT System for the Parallel Analysis of Oligonucleotide and RNAi Duplex Purity 171 Mirus Bio Discovers New Breakthrough Technology for RNAi Therapeutics 171 Kylin Therapeutics Signs License Agreement with Purdue University for RNAi Delivery Technology 172 Partnership Between Intradigm and Agilent to Develop RNA Interference Oncology Therapeutic 172 Alnylam Achieves Important Milestone in Collaborative Agreement 172 Launch of New RNAi Services Laboratory to Continue Research in Drug Discovery and Development 173 Alnylam Initiates New Research Program on RNAi Therapeutics 173 Alnylam Announces Advancement of New RNAi Therapeutic Development Program 173 Alnylam Grants License to Bio-Rad for Kreutzer-Limmer Patents in the RNAi Research Products Market 174 Luminex and Exiqon Jointly Produce New microRNAs Product Line 174 Mirus Bio Granted Broad RNAi Patent Using its Proprietary Hydrodynamic Intravascular Injection 175 Invitrogen Launches Advanced Transfection Reagents 175 Exiqon Establishes Sales Headquarters in the US 175 Mirus Bio Announces New Tool for Gene Function Analysis 175 Alnylam Grants Quark License to Develop and Commercialize RNAi Therapeutic Products 176 Exiqon Signs License Agreement with Max Planck Society for Diagnostic Use of Micro-RNAs 176 Abbott and Dharmacon Collaborate to Develop siRNA-Based Therapeutics 176 Acuity signs a pact with ZaBeCor for developing anti-inflammatory siRNA 177 Invitrogen Signs Agreement with genOway 177 Invitrogen Launches Stealth™ RNAi Human Kinase Collection 177 Novartis joins hands with Alnylam for RNAi Therapeutics Innovation 178 SB introduces Genome-Wide Human and Mouse siRNA Libraries 178 Analysis by Application 179 Exhibit 20. RNAi Applications – Global Market Estimations & Predictions (2005 -2020) by Type for Research, Therapeutics, Drug Development and Other in US$ Million 179 Exhibit 21. RNAi Applications - Global Market Shares (2010, 2015 & 2020) by Type for Research, Therapeutics, Drug Development and Other 180 Global Market for RNAi in Research 181 Exhibit 22. RNAi in Research - Global Market Estimations & Predictions (2005 - 2020) by Application for Functional Genomics, Protein Chemistry, Metabolism and Other in US$ Million 181 Exhibit 23. RNAi in Research - Global Market Shares (2010, 2015 & 2020) by Application for Functional Genomics, Protein Chemistry, Metabolism and Other 182 Exhibit 24. RNAi in Research - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 183 Exhibit 25. RNAi in Research - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 184 Exhibit 26. List of Global Companies/Organizations in RNAi Research 184 North American Market for RNAi in Research 185 Exhibit 27. RNAi in Research – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 185 Exhibit 28. RNAi in Research – North American Market Shares (2010, 2015 & 2020) for United States and Canada 186 United States Market for RNAi in Research 186 Canadian Market for RNAi in Research 186 European Market for RNAi in Research 187 Exhibit 29. RNAi in Research - European Market Estimations & Predictions (2005 - 2020)by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 187 Exhibit 30. RNAi in Research - European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 188 German Market for RNAi in Research 188 United Kingdom Market for RNAi in Research 188 Belgian Market for RNAi in Research 188 French Market for RNAi in Research 188 Russian Market for RNAi in Research 188 Asia-Pacific Market for RNAi in Research 189 Exhibit 31. RNAi in Research - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 189 Exhibit 32. RNAi in Research – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 190 Australian Market for RNAi in Research 190 Japanese Market for RNAi in Research 190 Chinese Market for RNAi in Research 190 Indian Market for RNAi in Research 190 South Korean Market for RNAi in Research 190 Rest of World Market for RNAi in Research 191 Exhibit 33. RNAi in Research – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 191 Exhibit 34. RNAi in Research – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 192 Brailian Market for RNAi in Research 192 Israelian Market for RNAi in Research 192 South African Market for RNAi in Research 192 RNAi in Functional Genomics 193 Global Market for RNAi in Functional Genomics 193 Exhibit 35. RNAi in Functional Genomics – Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 193 Exhibit 36. RNAi in Functional Genomics – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 194 North American Market for RNAi in Functional Genomics 195 Exhibit 37. RNAi in Functional Genomics – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 195 Exhibit 38. RNAi in Functional Genomics – North American Market Shares (2010, 2015 & 2020) for United States and Canada 196 European Market for RNAi in Functional Genomics 197 Exhibit 39. RNAi in Functional Genomics- European Market Estimations & Predictions (2005 - 2020)by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 197 Exhibit 40. RNAi in Functional Genomics - European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 198 Asia-Pacific Market for RNAi in Functional Genomics 199 Exhibit 41. RNAi in Functional Genomics- Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 199 Exhibit 42. RNAi in Functional Genomics – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 200 Rest of World Market for RNAi in Functional Genomics 201 Exhibit 43. RNAi in Functional Genomics – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 201 Exhibit 44. RNAi in Functional Genomics – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 202 RNAi in Protein Chemistry 203 Global Market for RNAi in Protein Chemistry 203 Exhibit 45. RNAi in Protein Chemistry– Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 203 Exhibit 46. RNAi in Protein Chemistry – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 204 North American Market for RNAi in Protein Chemistry 205 Exhibit 47. RNAi in Protein Chemistry – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 205 Exhibit 48. RNAi in Protein Chemistry – North American Market Shares (2010, 2015 & 2020) for United States and Canada 206 European Market for RNAi in Protein Chemistry 207 Exhibit 49. RNAi in Protein Chemistry - European Market Estimations & Predictions (2005 - 2020)by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 207 Exhibit 50. RNAi in Protein Chemistry - European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 208 Asia-Pacific Market for RNAi in Protein Chemistry 209 Exhibit 51. RNAi in Protein Chemistry- Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 209 Exhibit 52. RNAi in Protein Chemistry – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 210 Rest of World Market for RNAi in Protein Chemistry 211 Exhibit 53. RNAi in Protein Chemistry – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 211 Exhibit 54. RNAi in Protein Chemistry – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 212 RNAi in Metabolism 213 Global Market for RNAi in Metabolism 213 Exhibit 55. RNAi in Metabolism– Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 213 Exhibit 56. RNAi in Metabolism – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 214 North American Market for RNAi in Metabolism 215 Exhibit 57. RNAi in Metabolism – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 215 Exhibit 58. RNAi in Metabolism – North American Market Shares (2010, 2015 & 2020) for United States and Canada 216 European Market for RNAi in Metabolism 217 Exhibit 59. RNAi in Metabolism - European Market Estimations & Predictions (2005 - 2020)by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 217 Exhibit 60. RNAi in Metabolism - European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 218 Asia-Pacific Market for RNAi in Metabolism 219 Exhibit 61. RNAi in Metabolism- Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 219 Exhibit 62. RNAi in Metabolism – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 220 Rest of World Market for RNAi in Metabolism 221 Exhibit 63. RNAi in Metabolism – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 221 Exhibit 64. RNAi in Metabolism – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 222 RNAi in Other Research Applications 223 Global Market for RNAi in Other Research Applications 223 Exhibit 65. RNAi in Other Research Applications – Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 223 Exhibit 66. RNAi in Other Research Applications – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 224 North American Market for RNAi in Other Research Applications 225 Exhibit 67. RNAi in Other Research Applications – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 225 Exhibit 68. RNAi in Other Research Applications – North American Market Shares (2010, 2015 & 2020) for United States and Canada 226 European Market for RNAi in Other Research Applications 227 Exhibit 69. RNAi in Other Research Applications - European Market Estimations & Predictions (2005 - 2020)by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 227 Exhibit 70. RNAi in Other Research Applications - European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 228 Asia-Pacific Market for RNAi in Other Research Applications 229 Exhibit 71. RNAi in Other Research Applications- Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 229 Exhibit 72. RNAi in Other Research Applications – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 230 Rest of World Market for RNAi in Other Research Applications 231 Exhibit 73. RNAi in Other Research Applications – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 231 Exhibit 74. RNAi in Other Research Applications – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 232 RNAi Therapeutics 233 Exhibit 75. RNAi Therapeutics - Global Market Estimations & Predictions (2005 - 2020) by Application for Ophthalmology, Virology, Neurology, Oncology and Other in US$ Million 233 Exhibit 76. RNAi Therapeutics - Global Market Shares (2010, 2015 & 2020) by Application for Ophthalmology, Virology, Neurology, Oncology and Other 234 Exhibit 77. List of Global RNAi based Therapeutics Companies/Organization 234 Exhibit 78. Drug Development Status of RNAi based Therapeutics 235 Global Market for RNAi Therapeutics 237 Exhibit 79. RNAi Therapeutics - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 237 Exhibit 80. RNAi Therapeutics - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 238 North American Market for RNAi Therapeutics 239 Exhibit 81. RNAi Therapeutics – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 239 Exhibit 82. RNAi Therapeutics – North American Market Shares (2010, 2015 & 2020) for United States and Canada 240 United States Market for RNAi Therapeutics 240 Canadian Market for RNAi Therapeutics 240 European Market for RNAi Therapeutics 241 Exhibit 83. RNAi Therapeutics -European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 241 Exhibit 84. RNAi Therapeutics – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 242 German Market for RNAi Therapeutics 242 United Kingdom Market for RNAi Therapeutics 242 Belgian Market for RNAi Therapeutics 242 French Market for RNAi Therapeutics 242 Russian Market for RNAi Therapeutics 242 Asia-Pacific Market for RNAi Therapeutics 243 Exhibit 85. RNAi Therapeutics - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 243 Exhibit 86. RNAi Therapeutics – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 244 Australian Market for RNAi Therapeutics 244 Japanese Market for RNAi Therapeutics 244 Chinese Market for RNAi Therapeutics 244 Indian Market for RNAi Therapeutics 244 South Korean Market for RNAi Therapeutics 244 Rest of World Market for RNAi Therapeutics 245 Exhibit 87. RNAi Therapeutics – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 245 Exhibit 88. RNAi Therapeutics – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 246 Brazilian RNAi Therapeutics Market 246 Israeli RNAi Therapeutics Market 246 South African RNAi Therapeutics Market 246 RNAi in Ophthalmology 247 Global Market for RNAi in Ophthalmology 247 Exhibit 89. RNAi in Ophthalmology - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 247 Exhibit 90. RNAi in Ophthalmology - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 248 North American Market for RNAi in Ophthalmology 249 Exhibit 91. RNAi in Ophthalmology – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 249 Exhibit 92. RNAi in Ophthalmology – North American Market Shares (2010, 2015 & 2020) for United States and Canada 250 European Market for RNAi in Ophthalmology 251 Exhibit 93. RNAi in Ophthalmology - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 251 Exhibit 94. RNAi in Ophthalmology – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 252 Asia-Pacific Market for RNAi in Ophthalmology 253 Exhibit 95. RNAi in Ophthalmology - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 253 Exhibit 96. RNAi in Ophthalmology – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 254 Rest of World Market for RNAi in Ophthalmology 255 Exhibit 97. RNAi in Ophthalmology – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 255 Exhibit 98. RNAi in Ophthalmology – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 256 RNAi in Virology 257 Global Market for RNAi in Virology 257 Exhibit 99. RNAi in Virology - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 257 Exhibit 100. RNAi in Virology - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 258 North American Market for RNAi in Virology 259 Exhibit 101. RNAi in Virology – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 259 Exhibit 102. RNAi in Virology – North American Market Shares (2010, 2015 & 2020) for United States and Canada 260 European Market for RNAi in Virology 261 Exhibit 103. RNAi in Virology - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 261 Exhibit 104. RNAi in Virology – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 262 Asia-Pacific Market for RNAi in Virology 263 Exhibit 105. RNAi in Virology - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 263 Exhibit 106. RNAi in Virology – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 264 Rest of World Market for RNAi in Virology 265 Exhibit 107. RNAi in Virology – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 265 Exhibit 108. RNAi in Virology – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 266 RNAi in Neurology 267 Global Market for RNAi in Neurology 267 Exhibit 109. RNAi in Neurology - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 267 Exhibit 110. RNAi in Neurology - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 268 North American Market for RNAi in Neurology 269 Exhibit 111. RNAi in Neurology – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 269 Exhibit 112. RNAi in Neurology – North American Market Shares (2010, 2015 & 2020) for United States and Canada 270 European Market for RNAi in Neurology 271 Exhibit 113. RNAi in Neurology -European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 271 Exhibit 114. RNAi in Neurology – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 272 Asia-Pacific Market for RNAi in Neurology 273 Exhibit 115. RNAi in Neurology - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 273 Exhibit 116. RNAi in Neurology – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 274 Rest of World Market for RNAi in Neurology 275 Exhibit 117. RNAi in Neurology – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 275 Exhibit 118. RNAi in Neurology – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 276 RNAi in Oncology 277 Global Market for RNAi in Oncology 277 Exhibit 119. RNAi in Oncology - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 277 Exhibit 120. RNAi in Oncology - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 278 North American Market for RNAi in Oncology 279 Exhibit 121. RNAi in Oncology – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 279 Exhibit 122. RNAi in Oncology – North American Market Shares (2010, 2015 & 2020) for United States and Canada 280 European Market for RNAi in Oncology 281 Exhibit 123. RNAi in Oncology - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 281 Exhibit 124. RNAi in Oncology – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 282 Asia-Pacific Market for RNAi in Oncology 283 Exhibit 125. RNAi in Oncology - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 283 Exhibit 126. RNAi in Oncology – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 284 Rest of World Market for RNAi in Oncology 285 Exhibit 127. RNAi in Oncology – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 285 Exhibit 128. RNAi in Oncology – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 286 Other RNAi Therapeutics 287 Global Market for Other RNAi Therapeutics 287 Exhibit 129. Other RNAi Therapeutics - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 287 Exhibit 130. Other RNAi Therapeutics - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 288 North American Market for Other RNAi Therapeutics 289 Exhibit 131. Other RNAi Therapeutics – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 289 Exhibit 132. Other RNAi Therapeutics – North American Market Shares (2010, 2015 & 2020) for United States and Canada 290 European Market for Other RNAi Therapeutics 291 Exhibit 133. Other RNAi Therapeutics - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 291 Exhibit 134. Other RNAi Therapeutics – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 292 Asia-Pacific Market for Other RNAi Therapeutics 293 Exhibit 135. Other RNAi Therapeutics - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 293 Exhibit 136. Other RNAi Therapeutics – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 294 Rest of World Market for Other RNAi Therapeutics 295 Exhibit 137. Other RNAi Therapeutics – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 295 Exhibit 138. Other RNAi Therapeutics – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 296 RNAi in Drug Development 297 Exhibit 139. RNAi in Drug Development - Global Market Estimations & Predictions (2005 - 2020) by Application for Target Validation, Target Identification, Drug Mechanism and Other in US$ Million 297 Exhibit 140. RNAi in Drug Development - Global Market Shares (2010, 2015 & 2020) by Application for Target Validation, Target Identification, Drug Mechanism and Other 298 Global Market for RNAi in Drug Development 299 Exhibit 141. RNAi in Drug Development - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 299 Exhibit 142. RNAi in Drug Development - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 300 North American Market for RNAi in Drug Development 301 Exhibit 143. RNAi in Drug Development – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 301 Exhibit 144. RNAi in Drug Development – North American Market Shares (2010, 2015 & 2020) for United States and Canada 302 United States RNAi in Drug Development Market 302 Canadian RNAi in Drug Development Market 302 European Market for RNAi in Drug Development 303 Exhibit 145. RNAi in Drug Development - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 303 Exhibit 146. RNAi in Drug Development– European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 304 German RNAi in Drug Development Market 304 United Kingdom RNAi in Drug Development Market 304 Belgian RNAi in Drug Development Market 304 France RNAi in Drug Development Market 304 Russian RNAi in Drug Development Market 304 Asia-Pacific Market for RNAi in Drug Development 305 Exhibit 147. RNAi in Drug Development - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 305 Exhibit 148. RNAi in Drug Development– Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 306 Australian RNAi in Drug Development Market 306 Japan RNAi in Drug Development Market 306 Chinese RNAi in Drug Development Market 306 India RNAi in Drug Development Market 306 South Korea RNAi in Drug Development Market 306 Rest of World Market for RNAi in Drug Development 307 Exhibit 149. RNAi in Drug Development – Rest of Wolrd Market Estimations & Predictions (2005 - 2020) by Country for Brazil , Israel, South Africa and Other Countries in US$ Million 307 Exhibit 150. RNAi in Drug Development – Rest of Wolrd Market Shares (2010, 2015 & 2020) by Country for Brazil , Israel, South Africa and Other Countries in US$ Million 308 Brazilian RNAi in Drug Development Market 308 Israel RNAi in Drug Development Market 308 South Africa RNAi in Drug Development Market 308 RNAi in Target Validation 309 Global Market for RNAi in Target Validation 309 Exhibit 151. RNAi in Target Validation - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 309 Exhibit 152. RNAi in Target Validation - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 310 North American Market for RNAi in Target Validation 311 Exhibit 153. RNAi in Target Validation – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 311 Exhibit 154. RNAi in Target Validation – North American Market Shares (2010, 2015 & 2020) for United States and Canada 312 European Market for RNAi in Target Validation 313 Exhibit 155. RNAi in Target Validation - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 313 Exhibit 156. RNAi in Target Validation– European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 314 Asia-Pacific Market for RNAi in Target Validation 315 Exhibit 157. RNAi in Target Validation - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 315 Exhibit 158. RNAi in Target Validation– Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 316 Rest of World Market for RNAi in Target Validation 317 Exhibit 159. RNAi in Target Validation – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries in US$ Million 317 Exhibit 160. RNAi in Target Validation – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries 318 RNAi in Target Identification 319 Global Market for RNAi in Target Identification 319 Exhibit 161. RNAi in Target Identification - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 319 Exhibit 162. RNAi in Target Identification - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 320 North American Market for RNAi in Target Identification 321 Exhibit 163. RNAi in Target Identification – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 321 Exhibit 164. RNAi in Target Identification – North American Market Shares (2010, 2015 & 2020) for United States and Canada 322 European Market for RNAi in Target Identification 323 Exhibit 165. RNAi in Target Identification - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 323 Exhibit 166. RNAi in Target Identification– European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 324 Asia-Pacific Market for RNAi in Target Identification 325 Exhibit 167. RNAi in Target Identification - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 325 Exhibit 168. RNAi in Target Identification– Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 326 Rest of World Market for RNAi in Target Identification 327 Exhibit 169. RNAi in Target Identification – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 327 Exhibit 170. RNAi in Target Identification – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 328 RNAi in Drug Mechanism 329 Global Market for RNAi in Drug Mechanism 329 Exhibit 171. RNAi in Drug Mechanism - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 329 Exhibit 172. RNAi in Drug Mechanism - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 330 North American Market for RNAi in Drug Mechanism 331 Exhibit 173. RNAi in Drug Metabolism – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 331 Exhibit 174. RNAi in Drug Metabolism – North American Market Shares (2010, 2015 & 2020) for United States and Canada 332 European Market for RNAi in Drug Mechanism 333 Exhibit 175. RNAi in Drug Mechanism - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 333 Exhibit 176. RNAi in Drug Mechanism– European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 334 Asia-Pacific Market for RNAi in Drug Mechanism 335 Exhibit 177. RNAi in Drug Mechanism - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 335 Exhibit 178. RNAi in Drug Mechanism– Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 336 Rest of World Market for RNAi in Drug Mechanism 337 Exhibit 179. RNAi in Drug Metabolism – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 337 Exhibit 180. RNAi in Drug Metabolism – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 338 RNAi in Other Drug Development Applications 339 Global Market for RNAi in Other Drug Development Applications 339 Exhibit 181. RNAi in Other Drug Development Applications - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 339 Exhibit 182. RNAi in Other Drug Development Applications - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 340 North American Market for RNAi in Other Drug Development Applications 341 Exhibit 183. RNAi in Other Drug Development Applications – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million 341 Exhibit 184. RNAi in Other Drug Development Applications – North American Market Shares (2010, 2015 & 2020) for United States and Canada 342 European Market for RNAi in Other Drug Development Applications 343 Exhibit 185. RNAi in Other Drug Development Applications - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million 343 Exhibit 186. RNAi in Other Drug Development Applications– European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe 344 Asia-Pacific Market for RNAi in Other Drug Development Applications 345 Exhibit 187. RNAi in Other Drug Development Applications - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million 345 Exhibit 188. RNAi in Other Drug Development Applications– Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific 346 Rest of World Market for RNAi in Other Drug Development Applications 347 Exhibit 189. RNAi in Other Drug Development Applications – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 347 Exhibit 190. RNAi in Other Drug Development Applications – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million 348 Analysis by Tools/Products 349 Exhibit 191. RNAi Tools/Products – Global Market Estimations & Predictions (2005 - 2020) by Type for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million 349 Exhibit 192. RNAi Tools/Products – Global Market Shares (2010, 2015 & 2020) by Type for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other 350 RNAi Design/Software Market 351 Exhibit 193. RNAi Design/Software Tools/Products - Global Market Estimations & Predictions (2005 - 2020) by Type for MiRNA Target Scan, MiRNA Analysis Software, Design Algorithm and Other in US$ Million 351 Exhibit 194. RNAi Design/Software Tools/Products - Global Market Shares (2010, 2015 & 2020) by Type for MiRNA Target Scan, MiRNA Analysis Software, Design Algorithm and Other 352 Global RNAi Design/Software Market 353 Exhibit 195. RNAi Design/Software - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 353 Exhibit 196. RNAi Design/Software - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 354 North American RNAi Design/Software Market 355 Exhibit 197. RNAi Design/Software – North American Market Estimations & Predictions (2005 - 2020) for United States
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
